many instances OA is an acquired process secondary to various metabolic, mechanical, or inflammatory-immunological events. However, it has long been recognised that several distinct forms are inherited as dominant traits with a Mendelian pattern.2 3 The most common form of inherited OA is characterised by the presence of Heberden's and Bouchard's nodes and the concentric or uniform degeneration of the articular cartilage of several joints, particularly the hips and knees. 4 Many studies have examined the genetic factors that may be associated with either development or severity of this form of OA. Analysis of the frequencies of HLA antigens in various populations of patients affected have yielded conflicting results,5-9 although in one study an increased frequency of the HLA-A1B8 phenotype was observed.9 This study also examined the frequency of (x l-antitrypsin phenotypes in these individuals and found a significant increase in the MZ phenotype,9 although these results are unlikely to be related to the primary genetic defect in this form of OA. A second type of inherited OA is familial chondrocalcinosis-a disease in which calcium pyrophosphate dihydrate (CPPD) crystals are deposited in fibrous and hyaline cartilage.'0 The observations that the degenerative arthritis occasionally precedes or is not associated with demonstrable deposition of CPPD crystals"
and that there is a physical association of CPPD crystals with components of cartilage matrix'2 13 have led to the suggestion that cartilage matrix abnormalities may be a primary common event leading to cartilage degeneration, CPPD crystal deposition, or both. A third familial form of OA is known as Stickler syndrome or hereditary arthroophthalmopathy. 4 This syndrome is characterised by ophthalmological manifestations such as progressive vitreoretinal degeneration and severe myopia, peculiar facial features, and premature degenerative joint disease. Other heritable disorders accompanied by premature OA include hydroxyapatite deposition disease'5 and certain forms of multiple epiphysial dysplasias. '6 The pattern of inheritance of these diseases is consistent with the hypothesis that mutations in one or more of the genes encoding the macromolecular components of articular cartilage may be responsible for the premature and generalised degeneration of the tissue matrix. The abnormal genes could include the genes for cartilage matrix macromolecules, for enzymes involved in the biosynthesis of matrix, for hormone and growth factor receptors in chondrocytes, or for enzymes involved in the metabolic degradation of the tissue. Recent evidence, however, suggests that the genes encoding the collagenous components of cartilage matrix are the most likely candidates. The collagens represent the most abundant protein of articular cartilage matrix, comprising about 50% of the dry weight of the tissue. These molecules play a crucial role in the maintenance of the biomechanical properties of cartilage, being responsible for the tensile strength and shear stiffness of the tissue. The remarkable complexity of the organisation of the collagenous components in articular cartilage has recently become apparent'7 18 and at least five different collagen types representing the products encoded by at least 10 '9 These investigations have provided a number of successful strategies for the identification of structural mutations in procollagen genes. However, as discussed in more detail below, many of these strategies have limitations when applied to the study of mutations in the cartilage collagen genes, such as the limited availability of cartilage, the difficulty in expanding chondrocyte populations in vitro, the loss of chondrocyte-specific phenotype during culture, and the difficulty in performing 70imenez, Dharmavaram extensive protein characterisation from small tissue samples. The following sections will review some of the strategies that have been successfully utilised or that may be potentially useful to identify collagen gene mutations in inherited diseases affecting articular cartilage.
Restriction fragment length polymorphism (RFLP) analysis The development of recombinant probes that detect polymorphic sites in human DNA by RFLP analysis has made available a vast resource of genetic markers to follow the inheritance of specific DNA sequences in families.20 '22 These polymorphic sequences occur frequently in the flanking regions of most genes, as well as randomly throughout genomic DNA; their detection has made it possible to identify abnormal alleles of many genes and to trace their pattern of co-segregation with a given disease phenotype in families. The premise for RFLP study of inherited forms of OA is that, despite the heterogeneity and variability of their phenotype, they are caused by a primary genetic defect that resides at a specific chromosomal locus. The disease phenotype and the defective gene must, therefore, map to the same chromosomal location as reflected by their co-segregation in families. Using appropriate restriction enzymes it becomes feasible to map the inherited trait to a region in the chromosome bracketed by two specific markers.
The potential benefits of utilising RFLP genetic linkage analysis in heritable forms of human OA is that it will permit the identification of the genes at fault in these disorders. Even However, a large study of 61 patients with primary generalised OA failed to show a significant difference in the frequencies of one or more COL2A1 alleles between affected and control individuals.32 These results thus excluded the possibility that there is a common mutation at COL2A1 that is responsible for the disease phenotype. In a more recent study, Weaver et al" analysed the inheritance pattern of Hind-III and Hinf-I RFLPs of COL2A1 in a large five generation family with multiple epiphysial dysplasia (MED). The data indicated that the segregation patterns of COL2A1 and MED phenotype were discordant, with recombination observed in a minimum of two meioses in the portion of the family tested. From these results, it was determined that the MED locus in this family does not map within 2 centimorgans (cM) of COL2A1, therefore excluding this gene as the site of the mutation responsible for the disease phenotype. RFLPs in the type VI collagen gene were also tested for linkage with MED in this family. Recombination between COL6A2 and COL6A3 genes and MED was observed, also ruling them out as candidate genes. Moreover, the data excluded MED from a range of 5 cM on either side of the RFLP marker for COL6A1, effectively excluding COL6A1 as the candidate gene.
Despite the enormous potential of RFLP analysis for the identification of the defective genes in inherited diseases, the method has certain limitations. For example, RFLP analysis depends on the ability to identify large families in whom the disorder is clearly inherited, and from whom blood or tissue samples can be obtained from affected and non-affected members of three or more generations. Also, RFLP Another PCR based method that is being utilised as a screening method for detection of DNA sequence changes is the single strand conformation polymorphism (SSCP) analysis. The method involves amplification by PCR of a discrete segment of genomic DNA in the presence of radiolabelled nucleotides, temperature denaturation of the PCR products, and analysis of single strands on a non-denaturing polyacrylamide gel. Polymorphic differences in strand mobility result from the effects of primary sequence changes on the folded structure of a single DNA strand.
The primary sequence differences alter the intramolecular interactions that generate a three dimensional folded structure. The molecules may thus move at different rates through a non-denaturing polyacrylamide gel. Since the conformational variations are subtle, the success of any particular SSCP analysis experiment depends on several factors including the sequence of the DNA fragment being evaluated and optimisation of the experimental conditions to maximise differential migration among fragments. Under optimal conditions the efficiency of SSCP to detect DNA sequence differences such as polymorphisms or mutations has been reported to be close to 100%. Thus to sequence the entire coding region for the mutant allele is feasible; single base mutations or small insertions/deletions in coding or regulatory sequences can be identified; mutations in sequences important for splicing can also be detected utilising oligonucleotide primers specific for intronic sequences at the intron-exon boundaries. Thus the PCR amplified products will correspond to the coding sequences and to adjacent consensus sequences required for splicing. We have successfully used this approach and have amplified the entire type II collagen cDNA, a length of 4-4 kb, in only six fragments as shown in figure 1 , in which the length and position of the PCR fragments shown in A are illustrated in B. Sequencing of these PCR fragments indicated that their sequence was identical to that of corresponding regions of the human type II collagen cDNA reported previously.6' The RNA used in this experiment was obtained from freshly isolated 24 week old fetal chondrocytes. In order to determine the minimum amount of RNA required to amplify the entire type II -collagen cDNA, we performed PCR amplifi-A cation of RNA in concentrations ranging from 1 ,ug to 0.1 ng. We found that 1 ng of RNA was the smallest amount required to obtain amplification of each PCR fragment. In this experiment, 1 ,ug of RNA was obtained from 3 X 105 freshly isolated human fetal chondrocytes; therefore RNA equivalent to that obtained from only 300 chondrocytes was sufficient to obtain amplification of one fragment, or 1800 chondrocytes for amplification of the six fragments encompassing the entire type II collagen cDNA. Amplification of human type II collagen cDNA was also of obtained from chondrocytes from a small as postmortem specimen of articular cartilage id from a 75 year old woman immediately after ot isolation (fig 2A) , and after culture on porous Ly, hydroxyapatite ceramic crystals for 90 days ry ( fig 2B) . Thus even the small amounts of ne articular cartilage obtained from arthroplasty he or from arthroscopic surgery can be n successfully utilised to identify mutations in of COL2A1, by use of PCR. ve he n Identification of mutations that do not ie affect the coding sequence of COL2A1 ge In addition to the benefits of RFLP genetic of linkage analysis to identify the genes that may te be at fault in heritable OA, RFLP analysis can to give valuable negative information because the re absence of co-segregation (i.e. recombination) ic with the disease phenotype can exclude a ce candidate gene in a given family. Knowlton et re al9 showed the presence of recombination in as one of the families with Stickler syndrome they to studied. This observation conclusively ie excluded a mutation in COL2A1 as the cause d of the disease phenotype in this family. Similar rs analysis of another family with Stickler e syndrome and of a large family with severe 3e premature OA associated with CPPD 'e deposition failed to show co-segregation of a. COL2A1 polymorphisms with the disease indicated linkage to COL2A1 but sequencing of the entire coding sequence of the gene failed to show any mutation. In this family it was suggested that a mutation in the regulatory (promoter) regions of the gene that would not be detected by sequencing of the coding region of the gene may be responsible for the disease phenotype. In the past, attempts to identify mutations in collagen genes other than COL2A1, such as those coding for IX, X, or XI collagens, would have been nearly impossible with the small amounts of articular cartilage available to extract mRNA. We decided, therefore, to examine if the methods developed to amplify cDNA for type II collagen could be successfully utilised to amplify cDNA corresponding to the minor collagens present in the tissue, and attempted to amplify fragments of type IX and type XI collagen cDNA. As shown in figure 3A , we amplified 780 bp of the t 1 (IX) collagen chain: the length and position of the fragments shown in A are illustrated in B. We also amplified the entire published sequence of the ox2(XI) collagen cDNA which corresponds to 67% of the entire cDNA for this chain (fig 4) ; again, the figure shows the fragments, and their length and position. These studies demonstrated that a combination of PCR with primer-extension/reverse transcription can be utilised to amplify cDNA for the various articular cartilage collagens from mRNA obtained from fresh and cultured human chondrocytes.
From the results shown above, it is apparent that the use of cDNA for identification of mutations in type II and other collagens expressed in articular cartilage has several advantages over genomic sequence analysis. 
